Inotropic Agents

Inotropic agents are a class of cardiovascular medications that alter the force or energy of myocardial contractions, with clinical usage predominantly referring to positive inotropes that augment cardiac contractility

Inotropic agents are a class of cardiovascular medications that alter the force or energy of myocardial contractions, with clinical usage predominantly referring to positive inotropes that augment cardiac contractility

Inotropic agents are a class of cardiovascular medications that alter the force or energy of myocardial contractions, with clinical usage predominantly referring to positive inotropes that augment cardiac contractility These agents primarily work through distinct pharmacological mechanisms—such as beta-adrenergic receptor stimulation, phosphodiesterase enzyme inhibition, or modulation of intracellular calcium handling—to enhance stroke volume and cardiac output In clinical practice, they are pri...

These agents primarily work through distinct pharmacological mechanisms—such as beta-adrenergic receptor stimulation, phosphodiesterase enzyme inhibition, or modulation of intracellular calcium handling—to enhance stroke volume and cardiac output

These agents primarily work through distinct pharmacological mechanisms—such as beta-adrenergic receptor stimulation, phosphodiesterase enzyme inhibition, or modulation of intracellular calcium handling—to enhance stroke volume and cardiac output In clinical practice, they are primarily indicated for the management of acute decompensated heart failure, cardiogenic shock, and severe low-output states associated with cardiac surgery or refractory ventricular dysfunction to maintain systemic perfus...

These agents primarily work through distinct pharmacological mechanisms—such as beta-adrenergic receptor stimulation, phosphodiesterase enzyme inhibition, or modulation of intracellular calcium handling—to enhance stroke volume and cardiac output In clinical practice, they are primarily indicated for the management of acute decompensated heart failure, cardiogenic shock, and severe low-output states associated with cardiac surgery or refractory ventricular dysfunction to maintain systemic perfus...

In clinical practice, they are primarily indicated for the management of acute decompensated heart failure, cardiogenic shock, and severe low-output states associated with cardiac surgery or refractory ventricular dysfunction to maintain systemic perfusion